Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

I Panigrahi1, A Dixit, S Arora

  • 1Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.

Hematology (Amsterdam, Netherlands)
|July 16, 2005
PubMed
Summary

Hydroxyurea (HU) shows promise for thalassemia intermedia, with alpha deletions and Xmn I polymorphism potentially predicting a good response. This finding could personalize treatment for patients with this blood disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug repurposing in the management of major depressive disorder: a perspective.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan·2026
Same author

Colored Light Exposure Ensues Chronotype-Based Responses: Evidence From QEEG Analysis.

Physiological research·2025
Same author

An International ASXL3 Natural History Study: Deep Phenotypic Analyses Including Detailed Reports of a Milder Phenotype, Novel Associations, and Clinical Recommendations.

American journal of medical genetics. Part A·2025
Same author

Revisiting venous drainage of dorsum of foot for anatomical rationale behind venous ulcers, a cadaveric study.

La Clinica terapeutica·2025
Same author

Dose to Organ at Risk and its Characteristic Variation with the Clinically Used Different Prescription Levels for Early-stage Left-sided Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Thalassemia intermedia presents with diverse clinical outcomes.
  • Hydroxyurea (HU) offers potential therapeutic benefits for some patients.
  • Factors influencing HU response in thalassemia intermedia remain largely uncharacterized.

Purpose of the Study:

  • To investigate the correlation between molecular parameters (alpha-globin and beta-globin genotypes, Xmn I polymorphism) and hydroxyurea response in thalassemia intermedia.
  • To identify predictive markers for successful HU therapy.

Main Methods:

  • Twenty patients with thalassemia intermedia received HU at 10-20 mg/kg for one year.
  • Molecular analyses included alpha-globin and beta-globin genotyping and Xmn I polymorphism assessment.

Related Experiment Videos

  • Treatment response was evaluated by monitoring hemoglobin (Hb) and HbF levels and transfusion requirements.

    • Main Results:

    • Twelve out of twenty patients (60%) demonstrated a good response to HU, marked by increased Hb and HbF levels and reduced transfusion needs in four patients.
    • Alpha-globin deletions (-alpha(3.7)) were present in 33% of responders but absent in non-responders.
    • Synergistic effects between alpha deletions and Xmn I polymorphism were observed in responsive patients.

    Conclusions:

    • Alpha deletions may serve as an independent predictor of good response to HU in thalassemia intermedia.
    • The Xmn I polymorphism appears to act synergistically with alpha deletions in influencing HU efficacy.
    • Larger studies are warranted to confirm these predictive factors for personalized HU therapy.